Quantitative and mechanistic studies of Aβ immunotherapy

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 1, 2009, Pages 31-49

  Golde, Todd E ^a   Das, Pritam ^a   Levites, Yona ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3D6; MONOCLONAL ANTIBODY M266; UNCLASSIFIED DRUG; ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOIDOSIS; ANTIBODY PRODUCTION; BRAIN EDEMA; BRAIN HEMORRHAGE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; ANIMAL; DISEASE MODEL; IMMUNIZATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; EPITOPES; HUMANS; IMMUNIZATION; MICE; MICE, TRANSGENIC;

EID: 65649091306     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709787601830     Document Type: Review

References (107)

1. Golde, T.E. Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest., 2003, 111, 11-8.
2. Golde, T.E. Disease modifying therapy for AD? J. Neurochem., 2006, 99, 689-707.
3. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature, 1999, 400, 173-7.
4. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-9.
5. Vasilevko, V.; Cribbs, D.H. Novel approaches for immunotherapeutic intervention in Alzheimer's disease. Neurochem. Int., 2006, 49, 113-26.
6. Wisniewski, T.; Frangione, B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol., 2005, 15, 72-7.
7. Brody, D.L.; Holtzman, D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci., 2008, 31, 175-93.
8. Morgan, D. Immunotherapy for Alzheimer's disease. J. Alzheimers Dis., 2006, 9, 425-32.
9. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 9, 448-52.
10. Fox, N.C.; Black, R.S.; Gilman, S.; Rossor, M.N.; Griffith, S.G.; Jenkins, L.; Koller, M. Effects of A {beta} immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 2005.
11. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Boada, R.M.; Forette, F.; Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005.
12. Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61, 46-54.
13. Masliah, E.; Hansen, L.; Adame, A.; Crews, L.; Bard, F.; Lee, C.; Seubert, P.; Games, D.; Kirby, L.; Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 2005, 64:129-31.
14. Das, P.; Howard, V.; Loosbrock, N.; Dickson, D.; Murphy, M.P.; Golde, T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci., 2003, 23, 8532-8.
15. Bacskai, B.J.; Kajdasz, S.T.; McLellan, M.E.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B.T. Non-Fc mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci., 2002, 22, 7873-8.
16. Tamura, Y.; Hamajima, K.; Matsui, K.; Yanoma, S.; Narita, M.; Tajima, N.; Xin, K.Q.; Klinman, D.; Okuda, K. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol. Dis., 2005, 20, 541-9.
17. Levites, Y.; Jansen, K.; Smithson, L.A.; Dakin, R.; Holloway, V.M.; Das, P.; Golde, T.E. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci., 2006, 26, 11923-8.
18. Sagare, A.; Deane, R.; Bell, R.D.; Johnson, B.; Hamm, K.; Pendu, R.; Marky, A.; Lenting, P.J.; Wu, Z.; Zarcone, T.; Goate, A.; Mayo, K.; Perlmutter, D.; Coma, M.; Zhong, Z.; Zlokovic BV. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med., 2007, 13, 1029-31.
19. Matsuoka, Y.; Saito, M.; LaFrancois, J.; Gaynor, K.; Olm, V.; Wang, L.; Casey, E.; Lu, Y.; Shiratori, C.; Lemere, C.; Duff, K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci., 2003, 23, 29-33.
20. Bard, F.; Barbour, R.; Cannon, C.; Carretto, R.; Fox, M.; Games, D.; Guido, T.; Hoenow, K.; Hu, K.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, C.; Lee, M.; Motter, R.; Nguyen, M.; Reed, A.; Schenk, D.; Tang, P.; Vasquez, N.; Seubert, P.; Yednock, T. Epitope and isotype specificities of antibodies to beta - amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA, 2003, 100, 2023-8.
21. Ong, G.L.; Baker, A.E.; Mattes, M.J. Analysis of high complement levels in Mus hortulanus and BUB mice. J. Immunol. Meth., 1992, 154, 37-45.
22. Ong, G.L.; Mattes, M.J. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Meth, 1989, 125, 147-58.
23. Levites, Y.; Das, P.; Price, R.W.; Rochette, M.J.; Kostura, L.A.; McGowan, E.M.; Murphy, M.P.; Golde, T.E. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest., 2006, 116, 93-201.
24. Levites, Y.; Smithson, L.A.; Price, R.W.; Dakin, R.S.; Yuan, B.; Sierks, M.R.; Kim, J.; McGowan, E.; Reed, D.K.; Rosenberry, T.L.; Das, P.; Golde, T.E. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J., 2006, 20: 2576-8.
25. Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; Paul, S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci., 2002, 5: 452-7.
26. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Subbarao, S.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation, 2004, 1, 24.
27. Seubert, P.; Barbour, R.; Khan, K.; Motter, R.; Tang, P.; Kholodenko, D.; Kling, K.; Schenk, D.; Johnson-Wood, K.; Schroeter, S.; Gill, D.; Jacobsen, J.S.; Pangalos, M.; Basi, G.; Games, D. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener. Dis., 2008, 5, 65-71.
28. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.J.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St George-Hyslop, P.; Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408, 979-82.
29. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-5.
30. Chen, G.Q.; Chen, K.S.; Knox, J.; Inglis, J.; Bernard, A.; Martin, S.J.; Justice, A.; McConlogue, L.; Games, D.; Freedman, S.B.; Morris, R.G.M. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature, 2000, 408, 975-9.
31. Kotilinek, L.A.; Bacskai, B.; Westerman, M.; Kawarabayashi, T.; Younkin, L.; Hyman, B.T.; Younkin, S.; Ashe, K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci., 2002, 22, 6331-5.
32. Chauhan, N.B.; Siegel, G.J. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.J. Neurosci. Res., 2003, 74, 142-7.
33. Jensen, M.T.; Mottin, M.D.; Cracchiolo, J.R.; Leighty, R.E.; Arendash, G.W. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience, 2005, 130, 667-84.
34. Maier, M.; Seabrook, T.J.; Lazo, N.D.; Jiang, L.; Das, P.; Janus, C.; Lemere, C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci., 2006, 26, 4717-28.
35. Frenkel, D.; Maron, R.; Burt, D.S.; Weiner, H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest., 2005, 115, 2423-33.
36. Oddo, S.; Vasilevko, V.; Caccamo, A.; Kitazawa, M.; Cribbs, D.H.; LaFerla, F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem., 2006, 281, 39413-23.
37. Chen, G.; Chen, K.S.; Kobayashi, D.; Barbour, R.; Motter, R.; Games, D.; Martin, S.J.; Morris, R.G. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J. Neurosci., 2007, 27, 2654-62.
38. Mohajeri, M.H.; Saini, K.; Schultz, J.G.; Wollmer, M.A.; Hock, C.; Nitsch, R.M. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J. Biol. Chem., 2002, 277, 33012-7.
39. Brendza, R.P.; Bacskai, B.J.; Cirrito, J.R.; Simmons, K.A.; Skoch, J.M.; Klunk, W.E.; Mathis, C.A.; Bales, K.R.; Paul, S.M.; Hyman, B.T.; Holtzman, D.M. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest., 2005, 115, 428-33.
40. Das, P.; Murphy, M.P.; Younkin, L.H.; Younkin, S.G.; Golde, T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging, 2001, 22, 721-7.
41. Cleary, J.P.; Walsh, D.M.; Hofmeister, J.J.; Shnkar, G.M.; Kuskowski, M.A.; Selkoe, D.J.; Ashe, K.H. Natural Oligomers of the amyloid-beta peptide specifically disrupt cognitive function. Nat. Neurosci., 2005, 8, 79-84.
42. Lee, M.; Bard, F.; Johnson-Wood, K.; Lee, C.; Hu, K.; Griffith, S.G.; Black, R.S.; Schenk, D.; Seubert, P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol., 2005, 58, 430-5.
43. Hock, C.; Konietzko, U.; Papassotiropoulos, A.; Wollmer, A.; Streffer, J.; Rotz, R.V.; G, G.D.; Moritz E, Nitsch R. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med, 2002.
44. Sigurdsson, E.M.; Scholtzova, H.; Mehta, P.D.; Frangione, B.; Wisniewski, T. Immunization with a non-toxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol., 2001, 159, 439-47.
45. Sigurdsson, E.M.; Knudsen, E.; Asuni, A.; Fitzer-Attas, C.; Sage, D.; Quartermain, D.; Goni, F.; Frangione, B.; Wisniewski, T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci., 2004, 24, 6277-82.
46. Weiner, H.L.; Lemere, C.A.; Maron, R.; Spooner, E.T.; Grenfell, T.J.; Mori, C.; Issazadeh, S.; Hancock, W.W.; Selkoe, D.J. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol., 2000, 48, 567-79.
47. Lemere, C.A.; Beierschmitt, A.; Iglesias, M.; Spooner, E.T.; Bloom, J.K.; Leverone, J.F.; Zheng, J.B.; Seabrook, T.J.; Louard, D.; Li, D.; Selkoe, D.J.; Palmour, R.M.; Ervin, F.R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol., 2004, 165, 283-97.
48. Koller, M.F.; Mohajeri, M.H.; Huber, M.; Wollmer, M.A.; Roth Z'graggen, B.V.; Sandmeier, E.; Moritz, E.; Tracy, J.; Nitsch, R.M.; Christen, P. Active immunization of mice with an Abeta-Hsp70 vaccine. Neurodegener. Dis., 2004, 1: 20-8.
49. Schiltz, J.G.; Salzer, U.; Mohajeri, M.H.; Franke, D.; Heinrich, J.; Pavlovic, J.; Wollmer, M.A.; Nitsch, R.M.; Moelling, K. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J. Mol. Med., 2004, 82, 706-14.
50. Relkin, N.R.; Szabo, P.; Adamiak, B.; Burgut, T.; Monthe, C.; Lent, R.W.; Younkin, S.; Younkin, L.; Schiff, R.; Weksler, M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging, 2008.
51. Szabo, P.; Relkin, N.; Weksler, M.E. Natural human antibodies to amyloid beta peptide. Autoimmun. Rev., 2008, 7, 415-20.
52. Bacskai, B.J.; Kajdasz, S.T.; Christie, R.H.; Carter, C.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B.T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med., 2001, 7, 369-72.
53. Deane, R.; Sagare, A.; Hamm, K.; Parisi, M.; LaRue, B.; Guo, H.; Wu, Z.; Holtzman, D.M.; Zlokovic, B.V. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci., 2005, 25, 11495-503.
54. Oddo, S.; Billings, L.; Kesslak, J.P.; Cribbs, D.H.; LaFerla, F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004, 43, 321-32.
55. Bussiere, T.; Bard, F.; Barbour, R.; Grajeda, H.; Guido, T.; Khan, K.; Schenk, D.; Games, D.; Seubert, P.; Buttini, M. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am. J. Pathol., 2004, 165, 987-95.
56. Wilcock, D.M.; DiCarlo, G.; Henderson, D.; Jackson, J.; Clarke, K.; Ugen, K.E.; Gordon, M.N.; Morgan, D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci., 2003, 23, 3745-51.
57. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372, 216-23.
58. Patton, R.L.; Kalback, W.M.; Esh, C.L.; Kokjohn, T.A.; van Vickle, G.D.; Luehrs, D.C.; Kuo, Y.M.; Lopez, J.; Brune, D.; Ferrer, I.; Masliah, E.; Newel, A.J.; Beach, T.G.; Castano, E.M.; Roher, A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol., 2006, 169, 1048-63.
59. Petrushina, I.; Ghochikyan, A.; Mkrtichyan, M.; Mamikonyan, G.; Movsesyan, N.; Ajdari, R.; Vasilevko, V.; Karapetyan, A.; Lees, A.; Agadjanyan, M.G.; Cribbs, D.H. Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J. Neuroinflammation, 2008, 5, 42.
60. Racke, M.M.; Boone, L.I.; Hepburn, D.L.; Parsadainian, M.; Bryan, M.T.; Ness, D.K.; Piroozi, K.S.; Jordan, W.H.; Brown, D.D.; Hoffman, W.P.; Holtzman, D.M.; Bales, K.R.; Gitter, B.D.; May, P.C.; Paul, S.M.; DeMattos, R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci., 2005, 25, 629-36.
61. Schroeter, S.; Khan, K.; Barbour, R.; Doan, M.; Chen, M.; Guido, T.; Gill, D.; Basi, G.; Schenk, D.; Seubert, P.; Games, D. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci., 2008, 28, 6787-93.
62. Monsonego, A.; Imitola, J.; Petrovic, S.; Zota, V.; Nemirovsky, A.; Baron, R.; Fisher, Y.; Owens, T.; Weiner, H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Nail. Acad. Sci. USA, 2006, 103, 5048-53.
63. Floden, A.M.; Li, S.; Combs, C.K. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J. Neurosci., 2005, 25, 2566-75.
64. Hickman, S.E.; Allison, E.K.; El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci., 2008, 28, 8354-60.
65. Boche, D.; Nicoll, J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol., 2008, 18, 267-78.
66. Herber, D.L.; Mercer, M.; Roth, L.M.; Symmonds, K.; Maloney, J.; Wilson, N.; Freeman, M.J.; Morgan, D.; Gordon, M.N. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J. Neuroimmune. Pharmacol., 2007, 2, 222-31.
67. Takata, K.; Kitamura, Y.; Yanagisawa, D.; Morikawa, S.; Morita, M.; Inubushi, T.; Tsuchiya, D.; Chishiro, S.; Saeki, M.; Taniguchi, T.; Shimohama, S.; Tooyama, I. Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS Lett., 2007, 581, 475-8.
68. Koenigsknecht-Talboo, J.; Landreth, G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci., 2005, 25, 8240-9.
69. Town, T.; Laouar, Y.; Pittenger, C.; Mori, T.; Szekely, C.A.; Tan, J.; Duman, R.S.; Flavell, R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med., 2008, 14, 681-7.
70. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 2004, 24, 6144-51.
71. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 8850-5.
72. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Paul, S.M.; Holtzman, D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science, 2002, 295, 2264-7.
73. Vasilevko, V.; Xu, F.; Previti, M.L.; Van Nostrand, W.E.; Cribbs, D.H. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J. Neurosci., 2007, 27 ,13376-83.
74. McGowan, E.; Pickford, F.; Kim, J.; Onstead, L.; Eriksen, J.; Yu, C.; Skipper, L.; Murphy, M.P.; Beard, J.; Das, P.; Jansen, K.; Delucia, M.; Lin, W.L.; Dolios, G.; Wang, R.; Eckman, C.B.; Dickson, D.W.; Hutton, M.; Hardy, J.; Golde, T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron, 2005, 47, 191-9.
75. Kim, J.; Miller, V.M.; Levites, Y.; West, K.J.; Zwizinski, C.W.; Moore, B.D.; Troendle, F.J.; Bann, M.; Verbeeck, C.; Price, R.W.; Smithson, L.; Sonoda, L.; Wagg, K.; Rangachari, V.; Zou, F.; Younkin, S.G.; Graff-Radford, N.; Dickson, D.; Rosenberry, T.; Golde, T.E. BRI2 (ITM2b) inhibits abeta deposition in vivo. J. Neurosci., 2008, 28, 6030-6.
76. Kim, J.; Onstead, L.; Randle, S.; Price, R.; Smithson, L.; Zwizinski, C.; Dickson, D.W.; Golde, T.; McGowan, E. Abeta40 inhibits amyloid deposition in vivo. J. Neurosci., 2007, 27, 627-33.
77. Asami-Odaka, A.; Obayashi-Adachi, Y.; Matsumoto, Y.; Takahashi, H.; Fukumoto, H.; Horiguchi, T.; Suzuki, N.; Shoji, M. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener. Dis., 2005, 2, 36-43.
78. Bacher, M.; Depboylu, C.; Du, Y.; Noelker, C.; Staufenbiel, M.; Behr, T.; Henriksen, G.; Behe, M.; Dodel, R. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid antibodies in a transgenic mouse model of Alzheimer's disease. Neurosci. Lett., 2008.
79. Rubenstein, J.L.; Combs, D.; Rosenberg, J.; Levy, A.; McDermott, M.; Damon, L.; Ignoffo, R.; Aldape, K.; Shen, A.; Lee, D.; Grillo-Lopez, A.; Shuman, M.A. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 2003, 101, 466-8.
80. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-6.
81. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-66.
82. Glabe, C.C. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell. Biochem., 2005, 38, 167-77.
83. Tanzi, R.E. The synaptic Abeta hypothesis of Alzheimer disease. Nat. Neurosci., 2005, 8, 977-9.
84. Klein, W.L.; Stine, W.B. Jr., Teplow, D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging, 2004, 25, 569-80.
85. Lesne, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 2006, 440, 352-7.
86. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, I.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A.; Regan, CM.; Walsh, D.M.; Sabatini, B.L.; Selkoe, D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory, Nat. Med., 2008, 14, 837-42.
87. Klyubin, I.; Betts, V.; Welzel, A.T.; Blennow, K.; Zetterberg, H.; Wallin, A.; Lemere, C.A.; Cullen, W.K.; Peng, Y.; Wisniewski, T.; Selkoe, D.J.; Anwyl, R.; Walsh, D.M.; Rowan, M.J. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci., 2008, 28, 4231-7.
88. Walsh, D.M.; Selkoe, D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 2004, 44, 181-93.
89. Walsh, D.M.; Selkoe, D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett., 2004, 11, 213-28.
90. Glabe, C.G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging, 2006, 27, 570-5.
91. Wogulis, M.; Wright, S.; Cunningham, D.; Chilcote, T.; Powell, K.; Rydel, R.E. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J. Neurosci., 2005, 25, 1071-80.
92. Georganopoulou, D.G.; Chang, L.; Nam, J.M.; Thaxton, C.S.; Mufson, E.J.; Klein, W.L.; Mirkin, C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2005, 102, 2273-6.
93. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300, 486-9.
94. Lambert, M.P.; Viola, K.L.; Chromy, B.A.; Chang, L.; Morgan, T.E.; Yu, J.; Venton, D.L.; Krafft, G.A.; Finch, C.E.; Klein, W.L. Vaccination with soluble Abeta oligomers generates toxicity- neutralizing antibodies. J. Neurochem., 2001, 79, 595-605.
95. Golde, T.E.; Dickson, D.; Hutton, M. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr. Alzheimer. Res., 2006, 3, 421-30.
96. Fukuchi, K.; Tahara, K.; Kim, H.D.; Maxwell, J.A.; Lewis, T.L.; Accavitti-Loper, M.A.; Kim, H.; Ponnazhagan, S.; Lalonde, R. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis., 2006, 23, 502-11.
97. Kayed, R.; Head, E.; Sarsoza, F.; Saing, T.; Cotman, C.W.; Necula, M.; Margol, L.; Wu, J.; Breydo, L.; Thompson, J.L.; Rasool, S.; Gurlo, T.; Butler, P.; Glabe, C.G. Fibril, specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener., 2007, 2, 18.
98. Arendash, G.W.; Gordon, M.N.; Diamond, D.M.; Austin, L.A.; Hatcher, J.M.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Morgan, D. Behavioral assessment of Alzheimer's transgenic mice following long- term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol., 2001, 20, 737-44.
99. Austin, L.; Arendash, G.W.; Gordon, M.N.; Diamond, D.M.; DiCarlo, G.; Dickey, C.; Ugen, K., Morgan D. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav. Neurosci., 2003, 117, 478-84.
100. Buckwalter, M.S.; Coleman, B.S.; Buttini, M.; Barbour, R.; Schenk, D.; Games, D.; Seubert, P.; Wyss-Coray, T. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J. Neurosci., 2006, 26, 11437-41.
101. Nikolic, W.V.; Bai, Y.; Obregon, D.; Hou, H.; Mori, T.; Zeng, J.; Ehrhart, J.; Shytle, R.D.; Giunta, B.; Morgan, D.; Town, T.; Tan, J. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl. Acad. Sci. USA, 2007, 104, 2507-12.
102. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P.M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 2002, 298, 1379.
103. Hartman, R.E.; Izumi, Y.; Bales, K.R.; Paul, S.M.; Wozniak, D.F.; Holtzman, D.M. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci., 2005, 25, 6213-20.
104. Lee, E.B.; Leng, L.Z.; Zhang, B.; Kwong, L.; Trojanowski, J.Q.; Abel, T.; Lee, V.M. Targeting Amyloid-beta Peptide (Abeta) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Abeta Precursor Protein (APP) Transgenic Mice. J. Biol. Chem., 2006, 281, 4292-9.
105. Wilcock, D.M.; Alamed, J.; Gottschall, P.E.; Grimm, J.; Rosenthal, A.; Pons, J.; Ronan, V.; Symmonds, K.; Gordon, M.N.; Morgan, D. Deglycosylated antiamyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci., 2006, 26, 5340-6.
106. Lombardo, J.A.; Stern, E.A.; McLellan, M.E.; Kajdasz, S.T.; Hickey, G.A.; Bacskai, B.J.; Hyman, B.T. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci., 2003, 23, 10879-83.
107. Prada, C.M.; Garcia-Alloza, M.; Betensky, R.A.; Zhang-Nunes, S.X.; Greenberg, S.M.; Bacskai, B.J.; Frosch, M.P. Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J. Neurosci., 2007, 27, 1973-80.